Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.
Bijal D Shah, Chibuzo Iloabuchi, Sean Harrigan et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic literature review and meta-analysis evaluated the clinical, healthcare resource use, and quality-of-life outcomes of brexucabtagene autoleucel in adults with relapsed/refractory mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). The study found pooled overall response and complete response rates of 88% and 76% in MCL, and 74% complete response in B-ALL, with median overall survival of 40.3 months in MCL and 23.3 months in B-ALL.
Key findings
- Pooled overall response rate in MCL was 88%, with a complete response rate of 76%.
- In B-ALL, the complete response rate was 74%, with 73% achieving measurable residual disease negativity.
- Median overall survival was 40.3 months for MCL and 23.3 months for B-ALL.
- Severe adverse events were less frequent in real-world cohorts compared to clinical trials.
Why it matters
Understanding the real-world effectiveness and safety of brexucabtagene autoleucel is crucial for clinicians managing patients with relapsed/refractory MCL and B-ALL, as it informs treatment decisions and patient expectations.
What to keep in mind
Evidence gaps exist for health-related quality of life and economic outcomes, indicating a need for further research.